Intracameral amphotericin B injection in the management of deep keratomycosis.
OBJECTIVE
To report the use of intracameral amphotericin B in the management of deep keratomycosis.


METHODS
Four patients with deep keratomycosis unresponsive to conventional medical treatment underwent repeated intracameral injections of 5 microg amphotericin B in 0.1 mL 5% dextrose through a paracentesis. Three to 13 intracameral injections were given to each patient over 6 to 36 days.


RESULTS
Three of the four patients had complete resolution of the ulcer. The fourth patient perforated and required evisceration.


CONCLUSIONS
Preliminary experience suggests that intracameral injections of amphotericin B may have a role in the management of deep keratomycosis.
D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000382:microbiology* / Q000601:surgery; D005123:Eye; D017234:Eye Evisceration; D015821:Eye Infections, Fungal / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D019233:Retreatment; D016896:Treatment Outcome
D000935:Antifungal Agents; D000666:Amphotericin B